CCL2 is known to modulate the immunosuppressive state in tumors, and inhibition of its expression with DNMT-targeting drugs favors a more pro-inflammatory TME, reduces the number of Tregs and increases CD8+ T cells in lung cancer [202]. Here, CD8A is linked to lung cancer.